Diverse agenda underscores the widespread adoption of PBPK approaches throughout the drug development process PRINCETON, NJ – Oct. 19, 2015 – Certara®, the global biosimulation technology-enabled drug development company, today announced that its scientists are presenting 9 seminars and poster sessions at the twentieth International Society for the Study of Xenobiotics (ISSX). This annual ISSX … Continued
In a large (30 Million €) H2020-supported collaborative project, academia joins forces with small and medium-sized enterprises (SMEs), large industry, contract research organizations (CROs) and regulatory bodies to achieve a paradigm shift in toxicology towards a more efficient and animal-free chemical safety assessment. PRINCETON, NJ, Oct. 12, 2015 An international consortium of 39 partner organizations … Continued
Diverse agenda underscores the widespread adoption of pharmacometrics throughout the drug development process PRINCETON, NJ – Oct. 02, 2015 – Certara®, the global biosimulation technology-enabled drug development company, today announced that its scientists are presenting or co-authoring 14 workshops, seminars and poster sessions at the sixth American Conference on Pharmacometrics (ACoP6). This annual International Society … Continued
Achieving sufficient concentrations of antituberculosis (TB) drugs in pulmonary tissue at the optimum time is still a challenge in developing therapeutic regimens for TB. A physiologically based pharmacokinetic model incorporating a multi-compartment permeability-limited lung model was developed and used to simulate plasma and pulmonary concentrations of seven drugs. Passive permeability of drugs within the lung was predicted using an in vitro-in vivo extrapolation approach. Simulated epithelial lining fluid (ELF):plasma concentration ratios showed reasonable … Continued
